Wells Fargo’s Anbio Biotechnology NNNN Stock Holding History

Wells Fargo’s Portfolio NNNN Stock Details NNNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.57K	Hold	100	–	–	﹤0.01%	6219
2025 Q4	$3.01K	Hold	100	–	–	﹤0.01%	6173
2025 Q3	$3.73K	Hold	100	–	–	﹤0.01%	6111
2025 Q2	$3.17K	Buy	+100	New	+$957	﹤0.01%	6150

Other funds holding NNNN

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

BFS

Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Wells Fargo's NNNN Position: Q1 2026 in Review

Wells Fargo held its Anbio Biotechnology (NNNN) position steady in Q1 2026 at 100 shares worth $2.57K. The position accounts for ﹤0.01% of the portfolio, ranked #6219.

Wells Fargo first reported a position in NNNN in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.73K in Q3 2025. 8 funds tracked by Wall St. Rank hold NNNN as of Q1 2026.

Wells Fargo held 100 shares of Anbio Biotechnology worth $2.57K as of Q1 2026.
Wells Fargo left its Anbio Biotechnology share count unchanged in Q1 2026.
Anbio Biotechnology made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6219 holding.
Wells Fargo first reported a position in Anbio Biotechnology in Q2 2025 and has held it in 4 quarters since.
Wells Fargo's Anbio Biotechnology position peaked at $3.73K in Q3 2025.
8 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.